Quantcast

Latest The City of London Migraine Clinic Stories

2010-08-25 13:40:37

Research: Migraine with aura and risk of cardiovascular and all cause mortality in men and women: Prospective cohort study Individuals who suffer from migraines with aura (temporary visual or sensory disturbances before or during a migraine headache) are at a higher risk of dying from heart disease or stroke, according to research published today on bmj.com. This is the first large population-based study showing a link between migraine and overall mortality as well as specific mortality. The...

2010-07-13 06:00:00

MOUNTAIN VIEW, Calif., July 13 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced results from a clinical trial comparing the pharmacokinetics (PK) and safety of LEVADEX(TM) orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. The trial was designed to measure whether systemic absorption and exposure in smokers is greater than in non-smokers. In the trial, the systemic absorption of LEVADEX was not...

2010-06-25 07:00:00

A new study provides profound evidence of the cost of chronic migraine in terms of lost productive time at work. CHICAGO, June 25 /PRNewswire-USNewswire/ -- A new analysis from the American Migraine Prevalence and Prevention Study, one of the largest longitudinal studies of headache, indicates that employees suffering from Chronic Migraine (CM) experience increased lost productive time (LPT) in the workplace. Lost productive time (LPT) is estimated as the average weekly time lost due to...

2010-06-24 03:45:18

Researchers looking for the first time at how migraine sufferers experience the stigmatizing effects of their disease show that chronic migraine sufferers experience worse stigma than episodic migraine sufferers and more than those with other neurological diseases including stroke, epilepsy and MS. The research[i], presented at the American Headache Society's 52nd Annual Scientific Meeting in Los Angeles this week, was conducted at the Jefferson Headache Clinic at Thomas Jefferson University...

2010-06-10 06:00:00

MOUNTAIN VIEW, Calif., June 10 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX(TM) orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California. The late-breaker oral presentation titled "Utility of LEVADEX(TM) in Situations Where...

2010-06-09 07:05:00

DURHAM, N.C., June 9 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., ("CoLucid"), an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study. Results of this study will allow the...

2010-06-09 07:00:00

CHICAGO, June 9 /PRNewswire/ -- In celebration of National Headache Awareness Week, the National Headache Foundation (NHF), with the support of MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), today debuted an educational video podcast for patients and physicians, titled "What's on the Horizon in Acute Headache Treatment?" Click here to view the podcast. "It's an exciting time to be a migraine clinician, as there are a wealth of promising options for both acute and preventative treatment in...

2010-06-07 08:00:00

CHICAGO, June 7 /PRNewswire/ -- If an average day begins as a hectic race to get the kids off to school and get to work on time, imagine starting that day with a migraine. For many of the nation's 30 million migraine sufferers whose lives are often turned upside down by their migraines, relief can't come soon enough. In a new survey released today by the National Headache Foundation (NHF), 3 in 4 migraine sufferers said their current medication doesn't work fast enough to get them back to...

2010-05-11 06:00:00

MOUNTAIN VIEW, Calif., May 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today provided an update on its development program for LEVADEX(TM) orally inhaled migraine therapy. LEVADEX has completed Phase 3 efficacy development for the acute treatment of migraine. "We continue to make good progress with our LEVADEX program," said Timothy S. Nelson, President and CEO of MAP Pharmaceuticals. "Recent clinical and CMC discussions with the FDA have provided us with...

2010-04-14 06:00:00

MOUNTAIN VIEW, Calif., April 14 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced additional post-hoc analyses of data from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX(TM) orally inhaled migraine therapy showing efficacy in two difficult to treat patient subpopulations, menstrual migraine and migraine with allodynia. The data will be presented at the Annual Meeting of the American Academy of Neurology (AAN) in Toronto, Ontario. As...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.